Product Information
DPM-1001 is a novel, orally available tyrosine phosphatase inhibitor. DPM-1001 prevents the activation of protein phosphatases by inhibiting the enzyme responsible for removing phosphate groups from tyrosine residues. This leads to an accumulation of insulin receptor substrate 1 (IRS1) in cells, which is associated with type 2 diabetes and other metabolic diseases. In addition, DPM-1001 has been shown to inhibit cancer growth in vitro and in vivo, as well as to prevent neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The chemical structure of DPM-1001 is apigenin linked through a phosphate group to a quinoline moiety. The symptoms of DPM-1001 overdose are nausea, vomiting, diarrhea, abdominal pain, dizziness and headache.
Chemical properties
Technical inquiry about: 3D-WIC17227 DPM-1001
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
